| Description | AR3B is a human neutralizing antibody binding HCV E2, which is the main target for neutralizing antibodies. It has neutralization potency against HCV by targeting the E2 protein. This product has been tested using Enzyme-linked immunosorbent assay, Bio-layer interferometry and Neutralization assay. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | HCV |
| Epitope | Antigenic region 3 (a.a. 519-535) |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; Neut |
| Application Notes | For ELISA, the titrated Abs in dilution buffer with 1% nonfat dry milk was added to the microwells and incubated for 1 hour at room temperature. For Bio-layer interferometry (BLI), the antibody was performed at about 10 μg/mL in a kinetics buffer. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | HCV E2 |
| Alternative Name | Hepatitis C virus envelope glycoprotein E2 |
| Research Area | Infectious Disease |
| Related Disease | Liver failure, Hepatocellular carcinoma |
